MAPT and Alzheimer disease: Different studies on AD revealed that altered miRNAs levels including the miRNA-101, miRNA-106, miRNA124, miRNA-9, miRNA-134, miRNA-132, miRNA-29a/b, miRNA-107, miRNA-206, and miRNA-146 (Candido et al., 2019), play a critical role in the phenotypic changes during disease progression, particularly the production of Aβ, hyperphosphorylated tau, BACE1, and gamma-secretase expression and ADAM-secretase inhibition (detailed reviewed in Reddy et al., 2017).